HK1029052A1 - Inhibition of raf kinase using substituted heterocyclic ureas. - Google Patents
Inhibition of raf kinase using substituted heterocyclic ureas.Info
- Publication number
- HK1029052A1 HK1029052A1 HK00107684A HK00107684A HK1029052A1 HK 1029052 A1 HK1029052 A1 HK 1029052A1 HK 00107684 A HK00107684 A HK 00107684A HK 00107684 A HK00107684 A HK 00107684A HK 1029052 A1 HK1029052 A1 HK 1029052A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- inhibition
- raf kinase
- substituted heterocyclic
- heterocyclic ureas
- ureas
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
- C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99634397A | 1997-12-22 | 1997-12-22 | |
PCT/US1998/026078 WO1999032106A1 (en) | 1997-12-22 | 1998-12-22 | Inhibition of raf kinase using substituted heterocyclic ureas |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1029052A1 true HK1029052A1 (en) | 2001-03-23 |
Family
ID=25542800
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK00107684A HK1029052A1 (en) | 1997-12-22 | 2000-11-30 | Inhibition of raf kinase using substituted heterocyclic ureas. |
Country Status (27)
Country | Link |
---|---|
EP (1) | EP1047418B1 (bg) |
JP (3) | JP4437270B2 (bg) |
KR (1) | KR100571588B1 (bg) |
CN (2) | CN100360507C (bg) |
AT (1) | ATE300299T1 (bg) |
AU (1) | AU2198999A (bg) |
BG (1) | BG64984B1 (bg) |
BR (1) | BR9814374B1 (bg) |
CA (1) | CA2315717C (bg) |
CU (1) | CU23126A3 (bg) |
CZ (1) | CZ299156B6 (bg) |
DE (2) | DE69831013T2 (bg) |
DK (1) | DK1047418T3 (bg) |
ES (1) | ES2153340T3 (bg) |
GR (1) | GR20010300007T1 (bg) |
HK (1) | HK1029052A1 (bg) |
HU (1) | HUP0101704A3 (bg) |
ID (1) | ID26620A (bg) |
IL (2) | IL136767A0 (bg) |
NO (1) | NO326150B1 (bg) |
NZ (1) | NZ505844A (bg) |
PL (1) | PL205321B1 (bg) |
RU (1) | RU2232015C2 (bg) |
SK (1) | SK286213B6 (bg) |
TR (1) | TR200002618T2 (bg) |
UA (1) | UA71904C2 (bg) |
WO (1) | WO1999032106A1 (bg) |
Families Citing this family (147)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998052558A1 (en) * | 1997-05-23 | 1998-11-26 | Bayer Corporation | INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS |
US6291425B1 (en) * | 1999-09-01 | 2001-09-18 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
ES2154253T3 (es) * | 1997-12-22 | 2012-01-27 | Bayer Healthcare Llc | Inhibición de la actividad de p38 cinasa usando ureas heterocíclicas sustituidas. |
TR200002616T2 (tr) * | 1997-12-22 | 2000-11-21 | Bayer Corporation | Simetrik ve simetrik olmayan sübstitüe edilmiş difenil üreler kullanılarak raf kinazın inhibe edilmesi |
CA2359244C (en) | 1999-01-13 | 2013-10-08 | Bayer Corporation | .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
EP1157026A1 (en) | 1999-02-22 | 2001-11-28 | Boehringer Ingelheim Pharmaceuticals Inc. | Polycyclo heterocyclic derivatives as antiinflammatory agents |
US6395897B1 (en) | 1999-03-02 | 2002-05-28 | Boehringer Ingelheim Pharmaceuticals, Inc. | Nitrile compounds useful as reversible inhibitors of #9 cathepsin 5 |
WO2000055139A2 (en) | 1999-03-12 | 2000-09-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic urea and related compounds useful as anti-inflammatory agents |
DE60023853T2 (de) * | 1999-03-12 | 2006-05-24 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield | Aromatische heterozyklische verbindungen als antientzündungwirkstoffe |
ATE312823T1 (de) | 1999-07-09 | 2005-12-15 | Boehringer Ingelheim Pharma | Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen |
US6420364B1 (en) | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
US6492393B1 (en) | 1999-11-16 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
US6525046B1 (en) | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
US6608052B2 (en) | 2000-02-16 | 2003-08-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
FR2812633A1 (fr) * | 2000-08-04 | 2002-02-08 | Aventis Cropscience Sa | Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides |
US6645990B2 (en) | 2000-08-15 | 2003-11-11 | Amgen Inc. | Thiazolyl urea compounds and methods of uses |
US20020173507A1 (en) * | 2000-08-15 | 2002-11-21 | Vincent Santora | Urea compounds and methods of uses |
BR0113574A (pt) * | 2000-08-31 | 2003-07-22 | Pfizer Prod Inc | Derivados de pirazol e uso dos mesmos como inibidores de proteìna quinase |
KR100600550B1 (ko) | 2000-10-20 | 2006-07-13 | 에자이 가부시키가이샤 | 질소 함유 방향환 유도체 |
EP1341771A2 (en) | 2000-11-29 | 2003-09-10 | Glaxo Group Limited | Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors |
JP4366936B2 (ja) * | 2001-04-20 | 2009-11-18 | バイエル コーポレイション | キノリル、イソキノリルまたはピリジル尿素を使用するrafキナーゼの阻害 |
PL209822B1 (pl) * | 2001-04-27 | 2011-10-31 | Kirin Pharma Kk | Pochodna chinoliny lub chinazoliny, zawierająca ją kompozycja farmaceutyczna i zastosowanie |
WO2002092576A1 (en) | 2001-05-16 | 2002-11-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | Diarylurea derivatives useful as anti-inflammatory agents |
CA2448626A1 (en) | 2001-05-25 | 2002-12-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Carbamate and oxamide compounds as inhibitors of cytokine production |
AU2002317377A1 (en) * | 2001-07-20 | 2003-03-03 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
ES2275931T5 (es) * | 2001-12-03 | 2018-10-23 | Bayer Healthcare Llc | Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos |
JP4643909B2 (ja) * | 2001-12-21 | 2011-03-02 | ザ ウェルカム トラスト リミテッド | 遺伝子 |
WO2003068746A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Aryl ureas as kinase inhibitors |
US20040023961A1 (en) * | 2002-02-11 | 2004-02-05 | Bayer Corporation | Aryl ureas with raf kinase and angiogenisis inhibiting activity |
DK1478358T3 (da) | 2002-02-11 | 2013-10-07 | Bayer Healthcare Llc | Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese |
US10653684B2 (en) | 2002-02-11 | 2020-05-19 | Bayer Healthcare Llc | Aryl ureas with angiogenisis inhibiting activity |
EP1480973B1 (en) | 2002-02-25 | 2008-02-13 | Boehringer Ingelheim Pharmaceuticals Inc. | 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases |
MY156407A (en) | 2002-02-28 | 2016-02-26 | Novartis Ag | 5-phenylthiazole derivatives and use as p13 kinase inhibitors |
MXPA05000130A (es) * | 2002-06-27 | 2005-02-17 | Novo Nordisk As | Derivados de aril-carbonilo como agentes terapeuticos. |
CN1678311A (zh) | 2002-06-27 | 2005-10-05 | 诺沃挪第克公司 | 用作治疗剂的芳基羰基衍生物 |
PT1559715E (pt) * | 2002-10-21 | 2007-10-24 | Kirin Pharma Kk | Formas cristalinas de sais de n-[2-cloro-4-[6, 7-dimetoxi-4-quinolil)oxi]finil]-n'-(5-metil-3-isoxazolil) ureia |
EP2426122A1 (en) * | 2002-10-24 | 2012-03-07 | Merck Patent GmbH | Methylene urea derivative as RAF kinasse inhibitors |
US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
KR20050100615A (ko) | 2003-01-14 | 2005-10-19 | 싸이토키네틱스, 인코포레이티드 | 화합물, 조성물 및 방법 |
UY28213A1 (es) * | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
WO2004078746A2 (en) * | 2003-02-28 | 2004-09-16 | Bayer Pharmaceuticals Corporation | 2-oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatrory disorders |
JP5229853B2 (ja) | 2003-02-28 | 2013-07-03 | ニッポネックス インコーポレイテッド | 癌その他の疾患の治療に有用な新規な二環尿素誘導体 |
MXPA05010020A (es) * | 2003-03-24 | 2005-11-17 | Merck Patent Gmbh | Derivados de oxamida. |
WO2004085433A2 (en) * | 2003-03-28 | 2004-10-07 | Pharmacia & Upjohn Company Llc | Positive allosteric modulators of the nicotinic acetylcholine receptor |
EP1633758B1 (en) | 2003-05-15 | 2011-11-23 | Arqule, Inc. | Imidazothiazoles and imidazoxazole derivatives as inhibitors of p38 |
PT1626714E (pt) | 2003-05-20 | 2007-08-24 | Bayer Pharmaceuticals Corp | Diarilureias para doenças mediadas por pdgfr |
WO2005005389A2 (en) * | 2003-07-07 | 2005-01-20 | Merck Patent Gmbh | Malonamide derivatives |
ES2297490T3 (es) | 2003-07-23 | 2008-05-01 | Bayer Pharmaceuticals Corporation | Omega-carboxiarildifenilurea fluoro sustituida para el tratamiento y prevencion de enfermadades y afecciones. |
US7683172B2 (en) | 2003-11-11 | 2010-03-23 | Eisai R&D Management Co., Ltd. | Urea derivative and process for preparing the same |
CA2545711A1 (en) * | 2003-11-13 | 2005-06-02 | Ambit Biosciences Corporation | Urea derivatives as kinase modulators |
WO2005066145A1 (en) | 2004-01-06 | 2005-07-21 | Novo Nordisk A/S | Heteroaryl-ureas and their use as glucokinase activators |
TW200530236A (en) | 2004-02-23 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Heteroaryl phenylurea |
US20060211752A1 (en) | 2004-03-16 | 2006-09-21 | Kohn Leonard D | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression |
JP2007532615A (ja) * | 2004-04-13 | 2007-11-15 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
ATE517885T1 (de) | 2004-04-30 | 2011-08-15 | Bayer Healthcare Llc | Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs |
JP2008500284A (ja) * | 2004-05-12 | 2008-01-10 | ブリストル−マイヤーズ スクイブ カンパニー | 血栓症の治療に有用なp2y1レセプターのウレアアンタゴニスト |
CA2565519A1 (en) * | 2004-05-12 | 2005-12-01 | Schering Corporation | Cxcr1 and cxcr2 chemokine antagonists |
MXPA06014495A (es) | 2004-06-17 | 2007-03-01 | Cytokinetics Inc | Compuestos, composiciones y metodos. |
WO2006010082A1 (en) | 2004-07-08 | 2006-01-26 | Arqule, Inc. | 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase |
GEP20104973B (en) | 2004-08-12 | 2010-04-26 | Pfizer | Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors |
MY191349A (en) * | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
WO2006030826A1 (ja) | 2004-09-17 | 2006-03-23 | Eisai R & D Management Co., Ltd. | 医薬組成物 |
EP1645556A1 (en) * | 2004-10-07 | 2006-04-12 | Boehringer Ingelheim International GmbH | Arylpiperazine-benzoylamide derivatives useful as pharmaceutical agents |
CA2584368A1 (en) | 2004-10-19 | 2006-04-27 | Arqule, Inc. | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase |
ES2393741T3 (es) * | 2005-01-14 | 2012-12-27 | Gilead Connecticut, Inc. | Ureas 1,3-diarilsustituidas como moduladores de la actividad quinasa |
PL1858877T3 (pl) | 2005-01-14 | 2014-08-29 | Gilead Connecticut Inc | 1,3 podstawione diarylem moczniki jako modulatory aktywności kinazy |
JP5304241B2 (ja) | 2005-03-07 | 2013-10-02 | バイエル・ヘルスケア・エルエルシー | 癌の処置用のオメガ−カルボキシアリール置換ジフェニルウレアを含む医薬組成物 |
DE102005015253A1 (de) | 2005-04-04 | 2006-10-05 | Merck Patent Gmbh | Pyrazolderivate |
US7777040B2 (en) | 2005-05-03 | 2010-08-17 | Cgi Pharmaceuticals, Inc. | Certain substituted ureas, as modulators of kinase activity |
EP1925676A4 (en) | 2005-08-02 | 2010-11-10 | Eisai R&D Man Co Ltd | TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR |
US7538223B2 (en) | 2005-08-04 | 2009-05-26 | Cytokinetics, Inc. | Compounds, compositions and methods |
US8299252B2 (en) | 2005-08-05 | 2012-10-30 | Chugai Seiyaku Kabushiki Kaisha | Pyrazolopyridine and pyrrolopyridine multikinase inhibitors |
DE102005037499A1 (de) | 2005-08-09 | 2007-02-15 | Merck Patent Gmbh | Pyrazolderivate |
WO2007059202A2 (en) * | 2005-11-15 | 2007-05-24 | Bayer Healthcare Ag | Pyrazolyl urea derivatives useful in the treatment of cancer |
JP2009518298A (ja) * | 2005-12-01 | 2009-05-07 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | 癌治療に有用な尿素化合物 |
US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
US20070161617A1 (en) | 2005-12-15 | 2007-07-12 | Morgan Bradley P | Certain chemical entities, compositions and methods |
WO2007078815A2 (en) | 2005-12-16 | 2007-07-12 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
WO2007078839A2 (en) | 2005-12-19 | 2007-07-12 | Cytokinetics, Inc. | Compounds, compositions and methods |
EP1973897B1 (en) * | 2005-12-21 | 2014-05-21 | Bayer Intellectual Property GmbH | Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders |
WO2007076460A2 (en) * | 2005-12-23 | 2007-07-05 | Kalypsys, Inc. | Substituted thiazole ureas useful as inhibitors of protein kinases |
US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
KR101549364B1 (ko) | 2006-03-17 | 2015-09-01 | 암비트 바이오사이언시즈 코포레이션 | 질환 치료용 이미다졸로티아졸 화합물 |
TW200813039A (en) | 2006-04-19 | 2008-03-16 | Novartis Ag | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling |
WO2007136103A1 (ja) | 2006-05-18 | 2007-11-29 | Eisai R & D Management Co., Ltd. | 甲状腺癌に対する抗腫瘍剤 |
MX2008014953A (es) | 2006-05-26 | 2009-03-05 | Bayer Healthcare Llc | Combinaciones de medicamentos con diarilureas sustituidas para el tratamiento de cancer. |
DE102006029795A1 (de) * | 2006-06-27 | 2008-01-03 | Schebo Biotech Ag | Neue Harnstoff-Derivate und deren Verwendungen |
WO2008026748A1 (fr) | 2006-08-28 | 2008-03-06 | Eisai R & D Management Co., Ltd. | Agent antitumoral pour cancer gastrique non différencié |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
ES2699585T3 (es) | 2006-12-15 | 2019-02-11 | Nantbio Inc | Derivados de triazina y sus aplicaciones terapéuticas |
WO2008079972A2 (en) | 2006-12-20 | 2008-07-03 | Bayer Healthcare Llc | 4-{4- [ ({3-tert-butyl-1- [3- (hydroxymethyl) phenyl] - 1h- pyrazol- 5 -yl } carbamoyl) -amin o] -3-chlorophenoxy} -n-methylpyridine-2-carboxamide as an inhibitor of the vegfr kinase for the treatment of cancer |
CN101600694A (zh) | 2007-01-29 | 2009-12-09 | 卫材R&D管理有限公司 | 未分化型胃癌治疗用组合物 |
MX2009011343A (es) * | 2007-04-20 | 2009-11-05 | Deciphera Pharmaceuticals Llc | Inhibidores quinasa utiles para el tratamiento de enfermedades mieloproliferativas y otras enfermedades proliferativas. |
US8557830B2 (en) | 2007-06-07 | 2013-10-15 | Amgen Inc. | RAF kinase modulators and methods of use |
KR20150104231A (ko) | 2007-09-19 | 2015-09-14 | 암비트 바이오사이언시즈 코포레이션 | N-(5-tert-부틸-이속사졸-3-일)-N''-[4-[7-(2-모르폴린-4-일-에톡시)이미다조[2,1-B][1,3]벤조티아졸-2-일]페닐]우레아를 포함하는 고체 형태, 그의 조성물 및 그의 용도 |
CA2704000C (en) | 2007-11-09 | 2016-12-13 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
PE20091561A1 (es) | 2008-02-29 | 2009-10-30 | Array Biopharma Inc | Compuestos inhibidores de raf y metodos para su uso |
AR072657A1 (es) | 2008-02-29 | 2010-09-15 | Genentech Inc | Compuestos inhibidores de raf y metodos para su uso |
NZ591427A (en) | 2008-10-02 | 2012-12-21 | Respivert Ltd | P38 map kinase inhibitors |
WO2010067131A1 (en) * | 2008-12-11 | 2010-06-17 | Respivert Limited | P38 map kinase inhibitors |
CN105237530A (zh) | 2009-04-03 | 2016-01-13 | 豪夫迈罗氏公司 | 丙烷-1-磺酸{3-[5-(4-氯-苯基)-1H-吡咯并[2,3-b]吡啶-3-羰基]-2,4-二氟-苯基}-酰胺组合物及其用途 |
GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
BRPI1011318A2 (pt) | 2009-06-09 | 2019-09-24 | California Capital Equity Llc | derivados de triazina e suas aplicações terapêuticas |
CA2765044A1 (en) | 2009-06-09 | 2010-12-16 | California Capital Equity, Llc | Benzyl substituted triazine derivatives and their therapeutical applications |
WO2011057022A1 (en) | 2009-11-06 | 2011-05-12 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2011124923A2 (en) * | 2010-04-08 | 2011-10-13 | Respivert Limited | Novel compounds |
MX2012014776A (es) | 2010-06-25 | 2013-01-29 | Eisai R&D Man Co Ltd | Agente antitumoral que emplea compuestos con efecto inhibidor de cinasas combinados. |
WO2012008564A1 (ja) * | 2010-07-16 | 2012-01-19 | 協和発酵キリン株式会社 | 含窒素芳香族複素環誘導体 |
EP2594566A4 (en) | 2010-07-16 | 2014-10-01 | Kyowa Hakko Kirin Co Ltd | AROMATIC HETEROCYCLIC NITROGEN CYCLE DERIVATIVE |
US20130183268A1 (en) | 2010-07-19 | 2013-07-18 | Bayer Healthcare Llc | Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
PT2672967T (pt) | 2011-02-07 | 2018-12-07 | Plexxikon Inc | Compostos e métodos de modulação da quinase e suas indicações |
AU2012246490B2 (en) | 2011-04-18 | 2016-08-04 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
EP2714937B1 (en) | 2011-06-03 | 2018-11-14 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
EP2875014B1 (en) | 2012-07-17 | 2017-11-29 | Washington University | Anti-mucus drugs and uses therefor |
KR20150098605A (ko) | 2012-12-21 | 2015-08-28 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 퀴놀린 유도체의 비정질 형태 및 그의 제조방법 |
JP6411379B2 (ja) | 2013-05-14 | 2018-10-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する子宮内膜がん対象の応答性を予測及び評価するためのバイオマーカー |
US9750723B2 (en) | 2013-10-31 | 2017-09-05 | Ohio University | Prevention and treatment of non-alcoholic fatty liver disease |
JP6648108B2 (ja) | 2014-07-18 | 2020-02-14 | オハイオ ユニバーシティー | 生物学的シグナル伝達を改変するためのイミダゾール及びチアゾール組成物 |
CA2957785C (en) | 2014-08-11 | 2023-01-03 | Angion Biomedica Corporation | Cytochrome p450 inhibitors and uses thereof |
ES2926687T3 (es) | 2014-08-28 | 2022-10-27 | Eisai R&D Man Co Ltd | Derivado de quinolina muy puro y método para su producción |
BR112017004897A2 (pt) * | 2014-09-10 | 2017-12-12 | Glaxosmithkline Ip Dev Ltd | compostos inovadores como inibidores rearranjados durante a transfecção (ret) |
SG11201701694QA (en) * | 2014-09-10 | 2017-04-27 | Glaxosmithkline Ip Dev Ltd | Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors |
US9638690B2 (en) | 2014-11-07 | 2017-05-02 | The University Of British Columbia | Compounds and compositions for use as alkylating agent sensors and methods of use thereof |
CN107531631B (zh) | 2014-12-31 | 2021-09-03 | 安吉昂生物医药公司 | 用于治疗疾病的方法和药剂 |
US20180028662A1 (en) | 2015-02-25 | 2018-02-01 | Eisai R&D Management Co., Ltd. | Method for Suppressing Bitterness of Quinoline Derivative |
CA2978226A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharpe & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
CA2988707C (en) | 2015-06-16 | 2023-10-10 | Eisai R&D Management Co., Ltd. | Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer |
EP3500257A4 (en) | 2016-08-17 | 2020-01-22 | Icahn School of Medicine at Mount Sinai | KINASE INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER |
CN106866571B (zh) * | 2017-01-20 | 2018-06-29 | 中国药科大学 | 杂环脲类化合物及其药物组合物和应用 |
SG11202007198WA (en) | 2018-01-31 | 2020-08-28 | Deciphera Pharmaceuticals Llc | Combination therapy for the treatment of gastrointestinal stromal tumors |
CA3089630A1 (en) | 2018-01-31 | 2019-08-08 | Deciphera Pharmaceuticals, Llc | Combination therapy for the treatment of mastocytosis |
JP2021526130A (ja) | 2018-06-12 | 2021-09-30 | ブイティーブイ・セラピューティクス・エルエルシー | インスリンまたはインスリン類似体と組み合わせたグルコキナーゼ活性化薬の治療的使用 |
CN110903245B (zh) * | 2018-09-17 | 2022-11-22 | 南京药石科技股份有限公司 | 一种合成1-烷基-2-三氟甲基-5-氨基-1h-咪唑的关键中间体及其制备方法 |
WO2021013712A1 (en) * | 2019-07-19 | 2021-01-28 | Anagenesis Biotechnologies S.A.S. | Polyaromatic urea derivatives and their use in the treatment of muscle diseases |
TW202122082A (zh) | 2019-08-12 | 2021-06-16 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
MX2022001863A (es) | 2019-08-12 | 2022-05-30 | Deciphera Pharmaceuticals Llc | Metodos para tratar los tumores del estroma gastrointestinal. |
KR20220123058A (ko) | 2019-12-30 | 2022-09-05 | 데시페라 파마슈티칼스, 엘엘씨. | 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의 조성물 |
DK4084778T3 (da) | 2019-12-30 | 2023-12-11 | Deciphera Pharmaceuticals Llc | Amorfe kinaseinhibitorformuleringer og fremgangsmåder til anvendelse deraf |
WO2021180008A1 (zh) * | 2020-03-11 | 2021-09-16 | 暨南大学 | 含脲结构的三芳环化合物及其应用 |
WO2022135442A1 (zh) * | 2020-12-22 | 2022-06-30 | 上海拓界生物医药科技有限公司 | Cdk2抑制剂及其制备方法 |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
WO2024126777A1 (en) * | 2022-12-16 | 2024-06-20 | Astrazeneca Ab | Heteroaromatic compounds |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3754887A (en) * | 1969-05-05 | 1973-08-28 | Du Pont | Ureidopyrazoles defoliants |
JPS5031039A (bg) * | 1973-07-27 | 1975-03-27 | ||
US3990879A (en) * | 1974-12-26 | 1976-11-09 | Eli Lilly And Company | Method of controlling aquatic weeds |
US4183854A (en) * | 1976-11-10 | 1980-01-15 | John Wyeth & Brother Limited | Thiazole compound |
US4042372A (en) * | 1976-11-19 | 1977-08-16 | Eli Lilly And Company | Substituted thiadiazolotriazinediones and method of preparation |
JPS5386033A (en) * | 1977-10-20 | 1978-07-29 | Shionogi & Co Ltd | Herbicides |
DE3612830A1 (de) * | 1986-04-16 | 1987-10-22 | Basf Ag | Thiadiazolylharnstoff enthaltendes mittel zur entblaetterung von pflanzen |
FR2639636B1 (fr) * | 1988-11-30 | 1994-03-04 | Novapharme | Nouveaux composes heterocycliques a activite anticonvulsivante, procede de preparation et compositions therapeutiques les contenant |
JPH06500551A (ja) * | 1990-09-13 | 1994-01-20 | ビーチャム・グループ・パブリック・リミテッド・カンパニー | 5ht受容体アンタゴニストとしてのインドールウレア |
US5162360A (en) * | 1991-06-24 | 1992-11-10 | Warner-Lambert Company | 2-heteroatom containing urea and thiourea ACAT inhibitors |
US5185358A (en) * | 1991-06-24 | 1993-02-09 | Warner-Lambert Co. | 3-heteroatom containing urea and thiourea ACAT inhibitors |
JPH07504429A (ja) * | 1992-03-12 | 1995-05-18 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 5HT↓1cアンタゴニストとしてのインドール誘導体 |
WO1994014801A1 (en) * | 1992-12-29 | 1994-07-07 | Smithkline Beecham Plc | Heterocyclic urea derivatives as 5ht2c and 5ht2b antagonists |
AU3577995A (en) * | 1994-10-04 | 1996-04-26 | Fujisawa Pharmaceutical Co., Ltd. | Urea derivatives and their use as acat-inhibitors |
JPH11503110A (ja) * | 1995-02-17 | 1999-03-23 | スミスクライン・ビーチャム・コーポレイション | Il−8受容体拮抗剤 |
US5814646A (en) * | 1995-03-02 | 1998-09-29 | Eli Lilly And Company | Inhibitors of amyloid beta-protein production |
US5773459A (en) * | 1995-06-07 | 1998-06-30 | Sugen, Inc. | Urea- and thiourea-type compounds |
NZ332405A (en) * | 1996-04-23 | 2000-06-23 | Vertex Pharma | oxazolyl, thiazolyl or phenyl urea derivatives as inhibitors of inosine monophosphate dehydrogenase enzyme |
GB9623833D0 (en) * | 1996-11-16 | 1997-01-08 | Zeneca Ltd | Chemical compound |
CA2291065C (en) * | 1997-05-23 | 2010-02-09 | Bayer Corporation | Raf kinase inhibitors |
GB9723789D0 (en) * | 1997-11-12 | 1998-01-07 | Zeneca Ltd | Chemical compounds |
ES2154253T3 (es) * | 1997-12-22 | 2012-01-27 | Bayer Healthcare Llc | Inhibición de la actividad de p38 cinasa usando ureas heterocíclicas sustituidas. |
DE69834842T2 (de) * | 1997-12-22 | 2007-05-10 | Bayer Pharmaceuticals Corp., West Haven | Hemmung von raf-kinase unter verwendung von aryl- und heteroarylsubstituierten heterocyclischen harnstoffen |
-
1998
- 1998-12-22 CZ CZ20002350A patent/CZ299156B6/cs not_active IP Right Cessation
- 1998-12-22 DE DE69831013T patent/DE69831013T2/de not_active Expired - Lifetime
- 1998-12-22 HU HU0101704A patent/HUP0101704A3/hu unknown
- 1998-12-22 RU RU2000120184/15A patent/RU2232015C2/ru not_active IP Right Cessation
- 1998-12-22 KR KR1020007006929A patent/KR100571588B1/ko not_active IP Right Cessation
- 1998-12-22 ES ES98965981T patent/ES2153340T3/es not_active Expired - Lifetime
- 1998-12-22 DE DE1047418T patent/DE1047418T1/de active Pending
- 1998-12-22 NZ NZ505844A patent/NZ505844A/en not_active IP Right Cessation
- 1998-12-22 AT AT98965981T patent/ATE300299T1/de active
- 1998-12-22 ID IDW20001429A patent/ID26620A/id unknown
- 1998-12-22 AU AU21989/99A patent/AU2198999A/en not_active Abandoned
- 1998-12-22 JP JP2000525097A patent/JP4437270B2/ja not_active Expired - Fee Related
- 1998-12-22 SK SK963-2000A patent/SK286213B6/sk not_active IP Right Cessation
- 1998-12-22 TR TR2000/02618T patent/TR200002618T2/xx unknown
- 1998-12-22 CN CNB2004100286556A patent/CN100360507C/zh not_active Expired - Fee Related
- 1998-12-22 CA CA2315717A patent/CA2315717C/en not_active Expired - Fee Related
- 1998-12-22 WO PCT/US1998/026078 patent/WO1999032106A1/en active IP Right Grant
- 1998-12-22 DK DK98965981T patent/DK1047418T3/da active
- 1998-12-22 EP EP98965981A patent/EP1047418B1/en not_active Expired - Lifetime
- 1998-12-22 BR BRPI9814374-3B1A patent/BR9814374B1/pt not_active IP Right Cessation
- 1998-12-22 PL PL343083A patent/PL205321B1/pl not_active IP Right Cessation
- 1998-12-22 UA UA2000074352A patent/UA71904C2/uk unknown
- 1998-12-22 CN CNB988136236A patent/CN1149085C/zh not_active Expired - Fee Related
- 1998-12-22 IL IL13676798A patent/IL136767A0/xx active IP Right Grant
-
2000
- 2000-06-14 IL IL136767A patent/IL136767A/en not_active IP Right Cessation
- 2000-06-21 NO NO20003232A patent/NO326150B1/no not_active IP Right Cessation
- 2000-06-22 CU CU154A patent/CU23126A3/es not_active IP Right Cessation
- 2000-07-12 BG BG104597A patent/BG64984B1/bg unknown
- 2000-11-30 HK HK00107684A patent/HK1029052A1/xx not_active IP Right Cessation
-
2001
- 2001-02-28 GR GR20010300007T patent/GR20010300007T1/el unknown
-
2009
- 2009-10-15 JP JP2009237917A patent/JP2010065042A/ja active Pending
- 2009-10-15 JP JP2009237895A patent/JP2010065041A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GR20010300007T1 (en) | Inhibition of raf kinase using substituted heterocyclic ureas | |
HK1029989A1 (en) | Inhibition of raf kinase using aryl and heteroarylsubstituted heterocyclic ureas | |
GR20010300033T1 (en) | Raf kinase inhibitors | |
SI1070056T1 (en) | Phthalazinone pde iii/iv inhibitors | |
CA2291222A1 (en) | Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation | |
DK0901374T3 (da) | Tetrahydropteridiner og pyridylpiperaziner til behandling af neurologiske forstyrrelser | |
DE60020595D1 (de) | 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren | |
ATE281439T1 (de) | 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren | |
AU2003204708A1 (en) | Inhibition of Raf Kinase using Substituted Heterocyclic Ureas | |
SI0937075T1 (en) | New Imidazo- and Oxazolopyridines as Phosphodiesterase Inhibitors. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20131222 |